Atara Biotherapeutics announces 1-for-25 reverse stock split to comply with Nasdaq listing requirement

Atara Biotherapeutics, Inc.

Reverse stock split at 1-for-25 ratio effective June 20, 2024 at 12:01 a.m. ET; post-split trading starts same day.
Outstanding shares reduced from ~122.6M to ~4.9M; fractional shares paid in cash.
Split authorized by stockholders on June 10, 2024; board set final ratio same day.
Purpose: regain compliance with Nasdaq $1.00 minimum bid price for continued listing.
Pre-funded warrants adjusted from 32.15M pre-split to ~1.29M post-split, subject to fractional cash payments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.